Trade PURETECH HEALTH PLC ORD 1P - PRTC CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.0090 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023263% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001346% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | GBP | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United Kingdom of Great Britain and Northern Ireland | ||||||||
| Commission on trade | 0% |
| Prev. Close | 1.2105 |
| Open | 1.2185 |
| 1-Year Change | -41.73% |
| Day's Range | 1.2105 - 1.2425 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Apr 17, 2025 | 1.2285 | 0.0280 | 2.33% | 1.2005 | 1.2485 | 1.2005 |
| Apr 16, 2025 | 1.2105 | -0.0180 | -1.47% | 1.2285 | 1.2305 | 1.1985 |
| Apr 15, 2025 | 1.2445 | 0.0140 | 1.14% | 1.2305 | 1.2645 | 1.2305 |
| Apr 14, 2025 | 1.2525 | 0.0520 | 4.33% | 1.2005 | 1.2625 | 1.1845 |
| Apr 11, 2025 | 1.1705 | 0.1400 | 13.59% | 1.0305 | 1.1705 | 1.0285 |
| Apr 10, 2025 | 0.9985 | -0.1000 | -9.10% | 1.0985 | 1.1285 | 0.9985 |
| Apr 9, 2025 | 1.0145 | -0.1180 | -10.42% | 1.1325 | 1.1585 | 1.0025 |
| Apr 8, 2025 | 1.1525 | -0.1280 | -10.00% | 1.2805 | 1.2845 | 1.1525 |
| Apr 7, 2025 | 1.3085 | 0.1000 | 8.27% | 1.2085 | 1.3405 | 1.1885 |
| Apr 4, 2025 | 1.2685 | -0.1160 | -8.38% | 1.3845 | 1.3845 | 1.2685 |
| Apr 3, 2025 | 1.3845 | 0.0080 | 0.58% | 1.3765 | 1.4145 | 1.3485 |
| Apr 2, 2025 | 1.4165 | -0.0340 | -2.34% | 1.4505 | 1.4605 | 1.3685 |
| Apr 1, 2025 | 1.4665 | 0.0300 | 2.09% | 1.4365 | 1.4725 | 1.4005 |
| Mar 31, 2025 | 1.4365 | 0.0020 | 0.14% | 1.4345 | 1.4525 | 1.3785 |
| Mar 28, 2025 | 1.4605 | 0.1320 | 9.94% | 1.3285 | 1.4645 | 1.3185 |
| Mar 27, 2025 | 1.3385 | 0.0860 | 6.87% | 1.2525 | 1.3545 | 1.2225 |
| Mar 26, 2025 | 1.2665 | -0.0020 | -0.16% | 1.2685 | 1.2745 | 1.2565 |
| Mar 25, 2025 | 1.2785 | -0.0300 | -2.29% | 1.3085 | 1.3085 | 1.2765 |
| Mar 24, 2025 | 1.3085 | 0.0200 | 1.55% | 1.2885 | 1.3105 | 1.2785 |
| Mar 21, 2025 | 1.2585 | -0.0500 | -3.82% | 1.3085 | 1.3085 | 1.2585 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Puretech Health plc Company profile
PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines targeting serious diseases that result from dysfunctions in the nervous, immune, and gastrointestinal systems. The company is developing a digital medicine platform for the treatment and assessment of cognitive dysfunction across various neurological and psychiatric indications; therapies to treat a range of acute and chronic inflammatory disorders; microbiome-derived immune modulators for maternal and paediatric health; novel approach to oral delivery of biologics, vaccines, and other drugs; platform to address androgenetic alopecia; mechanotherapeutics to treat obesity, and other chronic diseases related to the gastrointestinal pathway; muscarinic receptor agonist programme for the treatment of psychosis and cognition, including schizophrenia and Alzheimer''s; monoclonal antibody-based therapeutic to treat pancreatic cancer and other solid tumors; voice-based technology platform for monitoring and diagnosing mental and physical medical conditions, such as depression, Alzheimer''s disease, multiple sclerosis, and Parkinson''s disease; platform and products that seek to explore and leverage the health potential of music; therapies for immune-mediated and infectious diseases based on rationally-defined consortium of human microbiome-derived bacteria; and novel antibody and cell therapies for treating cancer. It is also developing a milk exosome-based technology designed to enable the oral administration of biologics, nucleic acids, and complex small molecules; and a lipid prodrug technology to enable lymphatic targeting. In addition, the company''s medical device programme is developing a non-invasive neurostimulation treatment for psychiatric disorders, including depression and bipolar disorder. PureTech Health plc was incorporated in 2015 and is headquartered in Boston, Massachusetts.| Industry: | Biotechnology & Medical Research (NEC) |
6 Tide Street
Suite 400
BOSTON
MASSACHUSETTS 02210
US
News
ECB interest-rate forecasts – Projections for the next five years
The European Central Bank (ECB) plays a pivotal role in the economic stability of the eurozone, meaning ECB interest-rate forecasts are key to understanding how financial and economic scenarios might evolve.
14:37, 10 April 2025
BlackRock shareholders: Who owns the most BLK stock?
BlackRock is the leading asset manager in the world – but who are its biggest shareholders? Read on to find out.
13:46, 9 April 2025
Bitcoin price predictions 2025–2050: third-party price target
We examine bitcoin price predictions for 2025 and beyond, with insights from third-party analysts and market experts.
10:28, 9 April 2025
Tesla (TSLA) stock forecast 2025 and beyond: third-party Tesla price target
Where will Tesla’s stock be in five years? Can the EV company keep its crown?
08:19, 9 April 2025
JasmyCoin price predictions 2025-2030: Third-party price target
How might JASMY behave in the future?
16:13, 8 April 2025
Australian interest-rate projections: where will rates be in 5 years?
As one of the most closely watched economic indicators, Australian interest-rate projections offer valuable insight into the future of the country’s economy.
21:37, 7 April 2025
Copper price forecast: third-party price target
What’s next for the copper market? Read on for the latest analysis of the commodity's price and potential outlook.
17:31, 14 March 2025People also watch
Still looking for a broker you can trust?
Join the 720,000+ traders worldwide that chose to trade with Capital.com